EIGR News and Press, Eiger BioPharmaceuticals Inc. From 11/09/23

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Eiger BioPharmaceuticals Inc. (EIGR) is expected to report for Q3 2023

2023-09-13 09:58:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sigma Lithium (NASDAQ: SGML ) stock is climbing higher on Wednesday after confirming it received strategic proposals . According to a news release, Sigma Lithium’...

2023-09-13 09:39:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Workhorse (NASDAQ: WKHS ) stock is on the rise Wednesday, thanks to a new update from the IRS concerning its electric vehicle (EV) manufacturer status. The IRS has appro...

2023-09-13 09:20:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eiger BioPharmaceuticals (NASDAQ: EIGR ) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial . According to a press release...

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta PR Newswire PALO ALTO, Calif. , Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focus...

Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference PR Newswire PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the...

2023-08-14 17:20:38 ET Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q2 GAAP EPS of -$0.47 misses by $0.08 . Revenue of $4.64M (+13.4% Y/Y) beats by $0.07M . Cash, cash equivalents, and short-term debt securities as of June 30, 2023 totaled...

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage...